^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Pancreatic Cancer

Related cancers:
17h
c-Myc/GRPEL1 maintains fatty acid synthesis via FASN to support PDAC cell proliferation. (PubMed, Cell Death Dis)
These findings suggest that therapeutic inhibition of FA synthesis may be promising for treating PDAC patients with active c-Myc/GRPEL1/FASN signaling. Overall, this study demonstrates that FA synthesis mediated by the c-Myc/GRPEL1/FASN axis is essential for PDAC growth.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FASN (Fatty acid synthase)
17h
Pancreatic schwannoma: a diagnostic dilemma of pancreatic head tumour. (PubMed, BMJ Case Rep)
Due to diagnostic ambiguity, surgical resection is often mandated.We present a case of a female patient in her sixth decade of life presenting with symptoms pointing towards a malignant pancreatic head tumour. She underwent formal pancreatoduodenectomy, which on histopathological examination was diagnosed as a schwannoma.
Journal
|
SOX10 (SRY-Box 10)
17h
Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. (PubMed, J Gastrointest Surg)
Neoadjuvant SBRT achieves oncologic outcomes comparable to CFRT in BR/LA PC and is associated with greater adjuvant therapy use. A potential survival signal for SBRT in patients receiving FOLFIRINOX with CA19-9 > 1500U/mL is hypothesis-generating and warrants validation and formal interaction testing.
Journal
|
CA 19-9 (Cancer antigen 19-9)
|
5-fluorouracil • irinotecan • leucovorin calcium
17h
Tumor cell derived CCL20 exacerbates the immunosuppressive microenvironment by recruiting CCR6+ Tregs in pancreatic cancer. (PubMed, Cancer Lett)
Furthermore, CCR6 inhibition potentiated the efficacy of anti-PD1 immune checkpoint blockade. Taken together, our data demonstrate that tumor cell-derived CCL20 shapes an immunosuppressive microenvironment in pancreatic cancer by recruiting CCR6+ Tregs, suggesting that targeting the CCL20-CCR6 axis offers a promising therapeutic strategy, particularly when combined with immune checkpoint blockade.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CCL20 (C-C Motif Chemokine Ligand 20) • CCR6 (C-C Motif Chemokine Receptor 6)
20h
Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
gemcitabine • albumin-bound paclitaxel
21h
B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer. (clinicaltrials.gov)
P1, N=220, Recruiting, Poitiers University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Nov 2026 --> Feb 2028
Enrollment open • Trial completion date • Trial primary completion date
23h
KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We've All Been Waiting For. (PubMed, Clin Cancer Res)
Other immune partners might include vaccines, bispecific antibodies, and cell therapy. A major clinical opportunity eventually would be combining RAS inhibitors and immunotherapy in the adjuvant, neo-adjuvant, and interception settings, provided this new class of drugs is developed keeping its immune modulatory power in mind.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
1d
A Rare and Aggressive Klatskin Tumor Revealed by Magnetic Resonance Cholangiopancreatography (MRCP): A Diagnostic Case Report. (PubMed, Cureus)
The patient was promptly referred to a specialized hepatobiliary unit for evaluation of curative-intent resection. This case highlights how contemporary high-resolution MRCP combined with extreme CA 19-9 elevation can establish a confident noninvasive diagnosis of Klatskin tumor when initial ERCP fails, dramatically shortening diagnostic delay and accelerating the pathway to potentially curative surgery.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
1d
Gamma-glutamyl transferase as a redox-gatekeeper biomarker for pancreatic cystic neoplasms: A concise roadmap from epidemiology to bedside. (PubMed, World J Gastroenterol)
We propose: (1) Refining age-specific GGT thresholds via repeated measurements and restricted cubic splines; (2) Integrating GGT with carbohydrate antigen 19-9, carcinoembryonic antigen, and KRAS/GNAS circulating tumor DNA in machine-learning radiomic models for personalized 5-year malignancy risks per Fukuoka guidelines; and (3) Validating cost-effectiveness in multi-ethnic populations before screening. This repositions GGT as a globally available redox biosignature for PCN early detection, potentially reducing pancreatic cancer burden.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • IL6 (Interleukin 6) • CEACAM5 (CEA Cell Adhesion Molecule 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GNAS (GNAS Complex Locus) • IL6ST (Interleukin 6 Signal Transducer)